TOXICITY AND OUTCOME ANALYSIS OF PATIENTS WITH RECURRENT HEAD AND NECK CANCER TREATED WITH HYPERFRACTIONATED SPLIT-COURSE REIRRADIATION AND CONCURRENT CISPLATIN AND PACLITAXEL CHEMOTHERAPY FROM TWO PROSPECTIVE PHASE I AND II STUDIES

Background. Patients with local recurrences or new head and neck primary tumors in previously irradiated tissues have few options for salvage treatment. One option for select patients is to undergo reirradiation with concurrent chemo- therapy. The purpose of this study is to report the initial clinical results of the Fox Chase phase I and II prospective reirradiation and chemotherapy studies.